君实生物:与复星万邦签“偌考奇拜单抗”授权许可协议 获2.15亿元首付款

财中社
Jul 01

7月1日,君实生物(688180/01877)发布公告,公司与复星万邦签订了授权许可协议,公司授权复星万邦在大中华地区开发、注册、生产及商业化偌考奇拜单抗(JS005,抗IL-17A单抗)的权利。  公司将获得2.15亿元(含税)不可抵扣且不可退还的首付款,并有资格获得最高达11.25亿元(含税)的开发和销售里程碑付款,以及大中华地区净销售额双位数百分比的分级销售提成。  2026年一季度,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10